Vertex Pharmaceuticals is poised to announce its first-quarter earnings for 2025 after the market closes on Monday, May 5th. Analysts project robust financial results, anticipating earnings of $4.24 per share and revenue of $2.85 billion. The company has also set its fiscal year 2025 guidance at earnings per share.

As Regal Rexnord prepares to announce its first-quarter earnings for 2025, analysts predict a robust performance with an expected EPS of $1.82 and revenue reaching $1.38 billion.